|1.||Navab, Mohamad: 35 articles (12/2015 - 01/2002)|
|2.||Fogelman, Alan M: 32 articles (12/2015 - 01/2002)|
|3.||Anantharamaiah, G M: 29 articles (08/2015 - 03/2001)|
|4.||Rye, Kerry-Anne: 24 articles (11/2015 - 06/2004)|
|5.||Rader, Daniel J: 23 articles (10/2015 - 05/2002)|
|6.||Reddy, Srinivasa T: 23 articles (08/2015 - 09/2003)|
|7.||Remaley, Alan T: 18 articles (05/2015 - 04/2003)|
|8.||Kastelein, John J P: 17 articles (07/2015 - 10/2004)|
|9.||Schaefer, Ernst J: 16 articles (05/2015 - 10/2002)|
|10.||Asztalos, Bela F: 16 articles (05/2015 - 10/2002)|
03/18/2008 - "Acute plaque regression observed after short-term apoA-I(Milano) administration was associated with a significant reduction in suspected makers of plaque vulnerability in an experimental model of atherosclerosis."
06/03/1985 - "One molecular variant, Apo AI-Milano, while leading to a significant reduction of HDL, does not seem to be associated with clinical atherosclerosis, but rather with a protection from the disease. "
05/01/1992 - "Conclusively, apo A1 is effective in preventing the development of experimental atherosclerosis. "
08/18/2003 - "However, overexpression of apolipoprotein A-I in animals has been shown to reduce progression and even induce regression of atherosclerosis, indicating that apolipoprotein A-I is directly protective against atherosclerosis. "
02/01/2014 - "Apolipoprotein A-I protection against atherosclerosis is dependent on genetic background."
02/01/2010 - "We investigated whether the 5A peptide shares other beneficial features of apoA-I, such as protection against inflammation and oxidation. "
02/01/2011 - "Down-regulation of endothelial TLR4 signalling after apo A-I gene transfer contributes to improved survival in an experimental model of lipopolysaccharide-induced inflammation."
09/01/2013 - "Even more provocative are recent studies showing that apoA-I, the principle protein component of HDL modulates cellular inflammation and oxidation. "
01/01/2011 - "In this study, we hypothesized that an apoA-I mimetic peptide might be effective at inhibiting asthmatic airway inflammation. "
11/01/2015 - "ApoA-I restores the neovascularization capacity of the lymphatic system during TNF-mediated inflammation. "
|3.||Coronary Artery Disease (Coronary Atherosclerosis)
12/01/2013 - "The present study was designed to investigate whether the three-apolipoprotein (AI, B, E) gene polymorphisms were related to alter their plasma protein levels and hence associated to coronary artery disease (CAD). "
09/30/2008 - "These findings may be relevant to the study of a novel function of karyopherin beta3 and coronary artery diseases associated with apo A-I."
12/01/1998 - "This study was designed to examine the relationship between polymorphism at the Apo A1 gene and the risk of early coronary artery disease. "
10/01/1991 - "This study describes a variant of familial apoA-I deficiency associated with a moderate risk for premature coronary artery disease. "
01/01/1991 - "Coronary artery disease and apolipoprotein A-I/C-III gene polymorphism: a study of Saudi Arabians."
|4.||Cardiovascular Diseases (Cardiovascular Disease)
10/01/2013 - "In this study, we investigated whether MPO can oxidise HDL and determined MPO-specific oxidative signature by apoA-1 by peptide mapping in RA subjects with and without known cardiovascular disease (CVD). "
02/01/2015 - "N-Glycosylation of apolipoprotein A1 in cardiovascular diseases."
01/01/2015 - "The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the C-Terminal Helix: A New Rationale for Diagnosis and Treatment of Cardiovascular Disease?"
01/01/2013 - "These results show that HDL-apoA-I exchange is a clinically relevant measure of HDL function pertinent to cardiovascular disease. "
02/24/2012 - "These observations may have implications for treating cardiovascular disease, because recombinant apoA-I is under investigation as a therapeutic agent and mutant forms of apoA-I that resist oxidation might be more cardioprotective than the native form."
|5.||Vascular Diseases (Vascular Disease)
05/27/2011 - "Our results suggest that cleavage of lipid-free apoA-I by MMP-14 may contribute to reduced HDL formation, and this may be occurring during the development of various vascular diseases as lipid metabolism is disrupted."
10/01/2010 - "The results demonstrated accelerated oxidative damage to plasma ApoA-1, thus offering a potential mechanism underlying the impact of poor glycemic control in type 1 diabetic patients that affects a patient's risk for vascular disease."
03/27/2001 - "Despite very low plasma levels of HDL, carriers of the apolipoprotein AI Arg173 --> Cys mutation apoAI(Milano) (AIM) have no apparent increase in risk for atherosclerotic vascular disease. "
05/17/2002 - "Apolipoprotein A-I(Milano) (AIM), a natural variant of human apolipoprotein A-I, confers to carriers a significant protection against vascular disease. "
04/01/2000 - "To measure the blood apolipoprotein A-1 and apolipoprotein B in the fetal circulation in normal pregnancy and in pregnancy with evidence of vascular disease in the fetal umbilical placental circulation defined in the antenatal period by Doppler ultrasound study. "
|1.||Apolipoprotein A-I (Apolipoprotein A1)
|6.||Apolipoproteins B (ApoB)
|9.||LDL Receptors (LDL Receptor)
|3.||Diet Therapy (Therapy, Diet)
|4.||Renal Dialysis (Hemodialysis)
|5.||Drug Therapy (Chemotherapy)